FDA Determines Regulatory Review Period for ROZLYTREK TABLETS Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially determined the regulatory review period for the patent extension of ROZLYTREK TABLETS, a new drug application (NDA) 212725, following a request from the US Patent and Trademark Office (USPTO). This decision is a result of the submission of patent extension applications for the human drug product.